Literature DB >> 19900104

No association of EGF 5'UTR variant A61G and hepatocellular carcinoma in Chinese patients with chronic hepatitis B virus infection.

Peng Qi1, Hao Wang, Yue-Ming Chen, Xiao-Juan Sun, Yan Liu, Chun-Fang Gao.   

Abstract

OBJECTIVE: Epidermal growth factor (EGF) has many biological functions, including mitogenesis, tumorigenesis, and proliferation of epidermal tissues. Previous studies have reported that the EGF +61 (A/G) single nucleotide polymorphism in the 5'-untranslated region of the EGF gene is functional, and is associated with development of hepatocellular carcinoma (HCC) in liver cirrhosis and various malignancy. Our aim was to investigate whether EGF gene A61G polymorphism could be implicated in susceptibility to and/or clinicopathological characteristics of HCC in Chinese patients with chronic hepatitis B virus (HBV) infection.
METHODS: This polymorphism was studied in 387 patients with chronic HBV infection and in 208 healthy volunteers using restriction fragment-length polymorphism. The patients were divided into two groups: those without (n = 172) and those with HCC (n = 215). These 215 HCC patients with chronic HBV infection were designated as cases, and the remaining 172 patients without HCC served as controls.
RESULTS: There were no significant differences in EGF genotype or allelic frequencies between cases and controls nor was EGF genotype or allelic frequencies associated with tumour number, size, growth phase, stage, and invasiveness. We also found ethnic heterogeneity in the functional EGF polymorphism.
CONCLUSIONS: The present results show that although EGF gene A61G polymorphism is associated with development of HCC in liver cirrhosis, it is not sufficient for HCC in Chinese patients with chronic HBV infection.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19900104     DOI: 10.1080/00313020903071603

Source DB:  PubMed          Journal:  Pathology        ISSN: 0031-3025            Impact factor:   5.306


  13 in total

1.  Quantitative assessment of the effect of epidermal growth factor 61A/G polymorphism on the risk of hepatocellular carcinoma.

Authors:  Xian-Feng Shen; Xian-Tao Zeng; Zhi-Yuan Jian; Meng Zhou; Ping Zhou; Min Zhang
Journal:  Oncol Lett       Date:  2015-09-18       Impact factor: 2.967

2.  EGF61 polymorphism predicts complete pathologic response to cetuximab-based chemoradiation independent of KRAS status in locally advanced rectal cancer patients.

Authors:  Siwen Hu-Lieskovan; Daniel Vallbohmer; Wu Zhang; Dongyun Yang; Alexander Pohl; Melissa J Labonte; Peter P Grimminger; Arnulf H Hölscher; Robert Semrau; Dirk Arnold; Kathrin Dellas; Annelies Debucquoy; Karin Haustermans; Jean-Pascal H Machiels; Christine Sempoux; Claus Rödel; Matej Bracko; Vaneja Velenik; Heinz-Josef Lenz
Journal:  Clin Cancer Res       Date:  2011-06-14       Impact factor: 12.531

3.  Association between epidermal growth factor gene +61A/G polymorphism and the risk of hepatocellular carcinoma: a meta-analysis based on 16 studies.

Authors:  Guoping Jiang; Ke Yu; Lifang Shao; Xiaobo Yu; Chen Hu; Pei Qian; Haiyang Xie; Jinjun Li; Jie Zheng; Shusen Zheng
Journal:  BMC Cancer       Date:  2015-04-25       Impact factor: 4.430

4.  Association of epidermal growth factor and epidermal growth factor receptor polymorphisms with the risk of hepatitis B virus-related hepatocellular carcinoma in the population of North China.

Authors:  Jia Wu; Wei Zhang; Aiqiang Xu; Li Zhang; Tao Yan; Zhuo Li; Xiaopan Wu; Xilin Zhu; Juan Ma; Ke Li; Hui Li; Ying Liu
Journal:  Genet Test Mol Biomarkers       Date:  2013-06-22

5.  Carriage of the EGF rs4444903 A>G functional polymorphism associates with disease progression in chronic HBV infection.

Authors:  S Cmet; C Fabris; G Fattovich; E Falleti; D Bitetto; A Cussigh; E Fontanini; E Fornasiere; M Pirisi; P Toniutto
Journal:  Clin Exp Immunol       Date:  2012-02       Impact factor: 4.330

Review 6.  Pathogenic mechanisms in HBV- and HCV-associated hepatocellular carcinoma.

Authors:  Alla Arzumanyan; Helena M G P V Reis; Mark A Feitelson
Journal:  Nat Rev Cancer       Date:  2013-02       Impact factor: 60.716

7.  Epidermal growth factor 61A>G polymorphism is associated with risk of hepatocellular carcinoma: a meta-analysis.

Authors:  Zhiping Yang; Qiong Wu; Yongquan Shi; Yongzhan Nie; Kaichun Wu; Daiming Fan
Journal:  Genet Test Mol Biomarkers       Date:  2012-08-01

8.  Epidermal growth factor gene polymorphism and risk of hepatocellular carcinoma: a meta-analysis.

Authors:  Jian-Hong Zhong; Xue-Mei You; Wen-Feng Gong; Liang Ma; Yu Zhang; Qin-Guo Mo; Liu-Cheng Wu; Jun Xiao; Le-Qun Li
Journal:  PLoS One       Date:  2012-03-05       Impact factor: 3.240

9.  EGF rs4444903 polymorphism is associated with risk of HCV-related cirrhosis and HBV/HCV-related hepatocellular carcinoma.

Authors:  Jia Wang; Yanlin Zhong; Guixia Meng
Journal:  Int J Clin Oncol       Date:  2021-07-21       Impact factor: 3.402

10.  A functional polymorphism in the epidermal growth factor gene predicts hepatocellular carcinoma risk in Japanese hepatitis C patients.

Authors:  Masaya Suenaga; Suguru Yamada; Tsutomu Fujii; Bryan C Fuchs; Norio Okumura; Mitsuro Kanda; Daisuke Kobayashi; Chie Tanaka; Goro Nakayama; Hiroyuki Sugimoto; Masahiko Koike; Shuji Nomoto; Michitaka Fujiwara; Shin Takeda; Kazuhiko Hayashi; Kenneth K Tanabe; Hidemi Goto; Yasuhiro Kodera
Journal:  Onco Targets Ther       Date:  2013-12-13       Impact factor: 4.147

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.